Immuneering Corp (IMRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.82-4.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain sufficient cash and marketable securities to fund operations through 2029, ensuring financial stability for ongoing clinical development.
Stated as a priority in 5 of last 5 quarters. Cash, cash equivalents and marketable securities were $198.6 million at 2026-Q1 and $182.7 million at 2026-Q2. Management consistently expects the cash runway to fund operations into 2029, reflecting delivery on this financial stability priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“the Company expects its cash runway to be sufficient to fund operations into 2029.”
“the Company expects its cash runway to be sufficient to fund operations into 2029.”
“the Company expects its cash runway to be sufficient to fund operations into 2029.”
“the Company expects its cash runway to be sufficient to fund operations into 2029.”
“the Company expects its cash runway to be sufficient to fund operations into 2026.”
Progress the pivotal Phase 3 MAPKeeper 301 trial dosing and recruitment for atebimetinib combined with chemotherapy in first-line metastatic pancreatic cancer patients.
Stated as a priority in 2 of last 2 quarters. Management reported the Phase 3 MAPKeeper 301 trial is recruiting and dosing patients as of 2026-Q2, progressing on schedule from the 2026-Q1 update. This indicates delivery on the clinical trial advancement priority.
“Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date.”
“Pivotal Phase 3 MAPKeeper 301 trial now recruiting, with first patient dosing on track for mid-2026.”
Present and publish survival and tolerability data from Phase 2a trial of atebimetinib plus chemotherapy in first-line pancreatic cancer patients.
Stated as a priority in 2 of last 2 quarters. Management presented 17.3 month median overall survival data from 55 patients in the Phase 2a trial at 2026-Q2, following the 2026-Q1 announcement of upcoming data presentation. This shows progress in demonstrating clinical benefit.
“17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib + chemotherapy.”
“New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP to be presented at 2026 ASCO Annual Meeting.”
Begin dosing patients in Phase 2 trial combining atebimetinib with anti-PD-1 therapy in non-small cell lung cancer with preliminary data expected in late 2027.
Stated as a priority in 2 of last 2 quarters. Management confirmed plans to dose the first patient in the Phase 2 lung cancer trial in 2H 2026, consistent with prior quarter guidance. This indicates the company is on track with this clinical development milestone.
“2H 2026: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 in non-small cell lung cancer.”
“Phase 2 lung cancer trial is on track to dose the first patient in the second half of the year.”
Transition to new CFO Andrew Gengos to lead financial strategy, capital allocation, investor relations, and corporate development.
Newly stated in 2026-Q2. The appointment of Andrew Gengos as CFO was announced in mid-2026. This is a recent leadership change with no prior quarters stating this priority.
“Appointed Andrew Gengos as Chief Financial Officer and Treasurer.”
Over the trailing year it converted 1.03x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.